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Epidemiological studies indicate age as a strong risk factor for developing cardiovascular and neurodegenerative diseases. During
the aging process, changes in the expression of particular genes can inﬂuence the susceptibility to these diseases. 5-Lipoxygenase
(5-LO) by oxidizing fatty acids forms leukotrienes, potent mediators of oxidative and inﬂammatory reactions, two key pathogenic
events in both clinical settings. This enzyme is widely distributed in the cardiovascular as well as in the central nervous system,
where its expression levels increase with age, suggesting that it may be involved in their diseases of aging. The central theme of
this article is that during aging, 5-LO acts as biologic link between diﬀerent stressors and the development of cardiovascular and
neurodegenerative diseases. We hypothesize that the age-dependent upregulation of 5-LO represents a “priming” factor in the
vasculature as well as in the brain, where a subsequent exposure to triggering stimuli (i.e., infections) leads to an abnormal chronic
inﬂammatory reaction, and ultimately results in increased organ vulnerability and functional deﬁcits.
Copyright © 2009 J. Chu and D. Pratic` o. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Consistent demographic data show that due to the improve-
ments in public health and advances in medical therapy, the
number of older people (over 65 years) is fast increasing
worldwide, and it is expected to triple by 2040.
Since advancing age is the strongest risk factor for
developing chronic diseases, the burden from them is
expected to increase several-fold over the next 15–20 years.
This fact has created a sense of emergency toward this
segment of the population in view of the potential catas-
trophic socioeconomic consequences. Interestingly, age is a
nonmodiﬁable risk factor for atherosclerosis and chronic
neurodegenerative diseases such as Alzheimer’s disease (AD)
[1, 2] .T h ea g i n gp r o c e s si st h em o s tc o m m o nf e a t u r e
of the postreproductive phase of life. It manifests in all
multicellular organisms and is characterized by a progressive
reduction in the eﬃcacy of a number of physiological
processes. This decline translates to a reduced capacity to
maintain homeostatic control of important functions and
ﬁnally results in increased organ vulnerability.
In experimental models, for example, aged animals have
an exacerbation to experimental vascular injury and develop
atherosclerosis even on a chow diet [3]. On the other hand,
they also exhibit an impaired ability to sustain long-term
potentiation, a form of synaptic plasticity that has been
proposed as biological substrate for learning and/or memory
[4], and have impaired spatial learning in the Morris water
maze [5].
2.The 5-LOPathwayinthe Vasculature
andCentral NervousSystem
5-Lipoxygenase (5-LO) is a member of a large family of
enzymes, called lipoxygenases, which oxidizes free and ester-
iﬁed polyunsaturated fatty acids. 5-LO ﬁrst introduces active
molecular oxygen to carbon 5 of arachidonic acid resulting
in the formation of 5-Hydroxy-peroxy-eicosatetraenoic acid
(5HPETE). This unstable derivative is either reduced to
5-Hydroxy-eicosatetraenoic acid (5HETE), or converted to
leukotriene (LT) A4. However, LTA4 can serve either as
an intracellular intermediate in the synthesis of LTB4 and2 Cardiovascular Psychiatry and Neurology
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Figure 1: Schematic representation of the 5-Lipoxygenase enzyme
metabolic pathway. Arachidonic acid is released from diacyglycerol
or membrane phospholipids via the action of Phospholipase A2.
Once free, arachidonic acid is oxidized by 5-lipoxygenase (5-LO),
which has been activated by the Five-Lipoxygenase-Activating-
Protein(FLAP),atcarbon5toformtheunstable5-hydroxy-peroxy-
eicosatetraenoic acid (5HPETE), which is promptly metabolized
into the more stable 5-hydroxy-eicosatetraneoic acid (5HETE). The
5HETE can then be converted in leukotriene A4 (LTA4), which can
serve either as an intracellular intermediate in the synthesis of LTB4
and LTC4, or may be released extracellularly and subsequently be
taken up by adjacent cells devoid of 5-LO activity but expressing
LTA4-hydrolase and/or LTC4 synthase.
LTC4, or may be released extracellularly and subsequently
be taken up by adjacent cells devoid of 5-LO activity but
expressing LTA4-hydrolase and/or LTC4 synthase. LTs and
the cysteinyl derivatives of LTs all have strong pro-oxidant
and proinﬂammatory activities [6] (see Figure 1).
5-LO is widely expressed in the cardiovascular system,
that is, aorta, coronary, and carotid arteries, as well as in
macrophages and neutrophils. Interestingly, its expression
levels are increased in aortas of old animals when compared
with young ones [7]. This enzymatic pathway is also widely
expressed in the central nervous system (CNS), where it
localizes mainly in neuronal cells of the hippocampus and
cortex, and, similar to the vasculature, its levels increase
signiﬁcantly with aging [8, 9].
The expression of 5-LO is susceptible to hormonal
regulation, since higher levels are observed in conditions of
melatonin deﬁciency and/or hyperglucocorticoidemia [10,
11], both of which are common in elderly subjects [12].
Although in general upregulation of 5-LO might serve a
physiological purpose, during the aging process, it may also
increase the vulnerability of the cardiovascular system and
CNS to diﬀerent insults/stressors [13]. Given that older
subjects are at greater risk of health complications and
mortality stemming from altered inﬂammatory and immune
functions, and aging, via the upregulation of 5-LO, can be
an important risk factor, the eﬀects of stressors on this
enzymatic pathway are of particular importance.
3.5-LO,Aging andCardiovascularDiseases
Recent studies have implicated 5-LO in the pathogenesis
of atherosclerosis [14], and have also identiﬁed speciﬁc
5-LO genotypes in subpopulations with increased risk of
atherosclerosis [15, 16].
Age is an established risk factor for atherosclerosis.
Among primates and rodents, older animals develop more
extensive atherosclerosis than younger animals [17, 18]. Age-
accelerated vascular injury is commonly considered to result
from increased oxidative stress, leading to inﬂammation and
endothelial dysfunction [19]. Tissues from aged animals
demonstrate increase generation of reactive oxygen species
(ROSs) that lead to damage to vascular cells with age-
associated remodeling changes, and oxidation of lipids,
that is, leukotrienes, with potent proinﬂammatory and
proatherogenic actions [20, 21]. Interestingly, in experimen-
tal models of atherogenesis, the disease process can be exac-
erbated by inﬂammatory stress such as lipopolysaccharide
(LPS) exposure [22–24]. LPS binds to the Toll-like receptor
4 (TLR4) on the surface of a variety of cell types stimu-
lating, among other things, the generation of inﬂammatory
leukotrienes derived from the 5-LO pathway [25]. In this
setting, pharmacologic blockade of this enzyme or its genetic
deﬁciency aﬀords a signiﬁcant protective eﬀect against organ
injury and dysfunction [26]. These facts, together with the
upregulation of 5-LO in the aging vasculature support the
hypothesis that this enzymatic pathway plays a functional
role in the development of aging-related cardiovascular
diseases.
4. 5-LO, Aging and Neurodegenerative Diseases
In the CNS, aging, in general, is associated with an
increased incidence of chronic neurodegenerative processes,
and among them, AD is the most frequent [27, 28]. From
a biochemical point of view, brain aging is often associated
with microglia activation and a diﬀuse and chronic brain
inﬂammation involving also other cell types, that is, neurons
[29]. Interestingly, aged animals show greater increase in
central inﬂammatory cytokines compared with young adults
following both peripheral and central LPS administration
[30, 31]. This response is accompanied by a greater deﬁcit in
spatialworkingmemorythanisseeninyoungadultmice[32,
33], and suggests a possible modulatory role for 5-LO. Thus,
as stress appears to sensitize the CNS to subsequent insults,
so may aging with the upregulation of 5-LO sensitizes cells of
theimmunesystemtostressitself.Althoughthereisevidence
that stress can inﬂuence immune responses and memory
performance in elderly, however, the direct eﬀect of 5-LO on
these phenomena is still largely unknown. In the aging brain,
the prolonged stress-dependent inﬂammation status could
thenserveasprecursorforaugmentedneuronalvulnerability
which often culminates in cell death and loss of function.
Beside the inﬂammatory hypothesis, recent work has also
highlighted a novel concept that 5-LO can directly modulate
neurotransmitter receptors as well as amyloid beta peptide
metabolism, both of which are well-established mechanisms
involved in brain aging [34, 35].Cardiovascular Psychiatry and Neurology 3
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Figure 2: Hypothetical model whereby 5-Lipoxygenase inﬂuences brain and vascular pathological aging. During aging, peripheral and
central stressors targeting the vasculature and/or the central nervous system ﬁnd these organs primed to a chronic inﬂammatory status
secondary to the upregulation of 5-LO in endothelial cells and macrophages, neurons, and microglia, respectively. This fact facilitates an
abnormal and long-lasting inﬂammatory response, which ultimately results in increased organ vulnerability, functional impairments, and
development of pathology.
5. PeripheralStressors: Effect on Cardio-
vascularand NeurodegenerativeDiseases
Stress is a risk factor for pathological aging because elderly
individuals prone to psychological distress are more likely to
develop cardiovascular and/or neurodegenerative disorders
than age-matched controls, nonstressed individuals. Recent
studies suggest that activation of peripheral immune system
elicits a discordant inﬂammatory response in aged but, oth-
erwise, healthy subjects compared with younger cohorts, and
the reactive state of immune cells in the aged individuals has
been suggested as the basis for this abnormal inﬂammatory
response. We hypothesize that the upregulation of 5-LO in
the aging brain and vasculature by releasing high amount
of leukotrienes functions as priming factor for these organs
facilitating an abnormal inﬂammatory response to stressors,
which ultimately results in increased organ vulnerability and
functional impairments (Figure 2).
Importantly, while these responses are transient and
reversible in young, by contrast they are generally exacer-
bated and long-lasting in aged subjects.
In what follows, we brieﬂy discuss two models of stress
which have been widely used in the aging ﬁeld. Both of
them mimick in vivo biologically relevant situations: LPS,
as bacterial infection (very frequent in elderly); high levels
of glucocorticosteroids (as it is typically observed in aging)
[36, 37].
6.LPS
Administration of LPS has been widely used as a model to
trigger both vascular and neuroinﬂammatory responses [38–
41]. These inﬂammatory responses, in part mediated by 5-
LO activation, could act in concert with aging to accelerate
vascular and neuronal vulnerability and subsequent cell loss.
It is conceivable that the 5-LO upregulation in endothelial
cells and neurons, typical of the aging process, can function
as priming event toward macrophages/microglia in these
systemsandsensitizesthemtoanincreasedsusceptibilityand
abnormal biological response to stressors (Figure 2).
7.Glucocorticoids
Recent data suggest that glucocorticoid-sensitive mecha-
nism(s) are operative in increasing neuronal vulnerabil-
ity of the aging brain. Thus, high glucocorticoid levels
appear to be a constant feature of senile dementia [42].
Aged humans with prolonged elevated levels of corti-
sol exhibit reduced hippocampal volume and deﬁcits in
hippocampus-dependent memory tasks compared with nor-
mal cortisol controls. Further, glucocorticoids can nega-
tively aﬀect neuronal survival [43] in vitro, and impairs
cognition in vivo [44]. Similarly, a dysregulated cor-
tisol secretion, may be secondary to abnormalities in
the hypothalamic-pituitary-adrenal axis, has also been
involved in the failure to contain inﬂammatory reactions
within the vasculature [45, 46]. In both scenarios, the
age-dependent 5-LO upregulation could further sensitize
these organs to glucocorticoid-mediated detrimental eﬀects
(Figure 2).
In both cases, the hypothesis could be easily tested
considering the availability of diﬀerent selective inhibitors
of this enzymatic pathway, together with mice which are
genetically deﬁcient for this enzyme. Thus, treating aged
animals with LPS or corticosteroids in the presence of the
inhibitors, or aged 5-LO knock-out and wild-type mice
with the same stressors could provide us with important
information supporting the functional role of this metabolic
pathway.
8. Conclusions
Because of the projected aging of the human population,
the burden from diseases of aging is expected to increase
dramatically over the next 20–25 years. The identiﬁcation of
a putative common molecular mechanism inﬂuencing these
diseases and amenable of a therapeutic modulation would
result not only in an improvement of the quality of life for
this segment of the population but also in a signiﬁcantly
reduced socio-economic impact of these diseases. The fact
that the 5-LO is signiﬁcantly increased with aging, which
associates with the development of cardiovascular as well as4 Cardiovascular Psychiatry and Neurology
neurodegenerative diseases, makes this enzymatic pathway
an excellent candidate that fulﬁlls these criteria.
Several molecular mechanisms have been invoked for the
5-LO-mediatedage-dependentincreasedcardiovascularrisk,
and most of them involve modulation of the inﬂammatory
vascular response to stressors. By contrast, much less is
known about the molecular mechanisms operating in the 5-
LO-mediated pathologic brain aging. Beside the role of 5-LO
in regulating neuroinﬂammation, more recent works have
pointed out some novel mechanisms and pathways whereby
this enzyme may be involved in pathological brain aging,
that is, neurotransmitter receptors and amyloid beta peptide
metabolism.
Future studies are warranted to provide a more con-
clusive evidence for this association, and new or revisited
common molecular mechanisms responsible for it.
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